Overview

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a single dose, open-label, single or multiple center study to determine the interaction of ketoconazole with ABT-263 in approximately 12 subjects with cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Abbott
Treatments:
Ketoconazole
Navitoclax